![Steven Lo](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Steven Lo
Algemeen Directeur bij
VAXART, INC.
Vermogen: 339 015 $ op 30-06-2026
Profiel
Steven Lo is President, Chief Executive Officer & Director at Vaxart, Inc. since 2024.
Formerly, Mr. Lo was Chief Executive Officer & Director at Valitor, Inc. from 2022 to 2024; President, Chief Executive Officer & Director at Zosano Pharma Corp.
from 2019 to 2022; Chief Commercial Officer at Puma Biotechnology, Inc. from 2015 to 2019; Chief Commercial Officer & Senior Vice President at Corcept Therapeutics, Inc. from 2013 to 2015; Senior Director-Oncology Marketing at Genentech, Inc. from 1997 to 2010; Principal at Kaiser Permanente Washington Health Research Institute; and Member at Roche Group.
Education includes graduate studies at the University of Southern California and undergraduate studies at the University of California, Davis.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
VAXART, INC. 0,23% | 26-05-2026 | 560.356 ( 0,23% ) | 339 015 $ | 30-06-2026 |
Actieve functies van Steven Lo
| Bedrijven | Functie | Begin |
|---|---|---|
| VAXART, INC. | Algemeen Directeur | 18-03-2024 |
Eerdere bekende functies van Steven Lo
| Bedrijven | Functie | Einde |
|---|---|---|
Valitor, Inc.
 Valitor, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops novel methods of modifying therapeutic proteins | Algemeen Directeur | 01-03-2024 |
| ZOSANO PHARMA CORPORATION | Algemeen Directeur | 01-08-2022 |
| PUMA BIOTECHNOLOGY, INC. | Corporate Officer/Principal | 04-10-2019 |
| CORCEPT THERAPEUTICS INCORPORATED | Corporate Officer/Principal | 04-09-2015 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | - |
Opleiding van Steven Lo
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
94
Eerstegraads connecties
10
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 10 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Corcept Therapeutics, Inc.
 Corcept Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery and development of drugs which treat severe metabolic, oncologic and neuropsychiatric disorders | Health Technology |
Kaiser Permanente Washington Health Research Institute
 Kaiser Permanente Washington Health Research Institute Hospital/Nursing ManagementHealth Services Provides healthcare plans and services | Health Services |
University of Southern California
 University of Southern California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Group
 Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
University of California, Davis
 University of California, Davis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zosano Pharma Corp.
 Zosano Pharma Corp. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that specializes in the systemic administration of therapeutics | Health Technology |
Puma Biotechnology, Inc.
 Puma Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer | Health Technology |
Vaxart, Inc.
 Vaxart, Inc. BiotechnologyHealth Technology Develops vaccines | Health Technology |
Valitor, Inc.
Valitor, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops novel methods of modifying therapeutic proteins | Health Technology |
